Osimertinib (Tagrisso) costs them nearly $11000 a month in New Zealand because it is not funded by Pharmac and it is not covered under any health insurance.
In the US, Tagrisso will cost them just $700 a month under the country's ACA (Affordable Care Act) insurance.